Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms
Language English Country Japan Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Fusion Proteins, bcr-abl genetics MeSH
- Quinazolines therapeutic use MeSH
- Adult MeSH
- Platelet Aggregation Inhibitors therapeutic use MeSH
- Janus Kinase 2 genetics MeSH
- Middle Aged MeSH
- Humans MeSH
- Mutation MeSH
- Myeloproliferative Disorders complications diagnosis genetics MeSH
- Risk Factors MeSH
- Aged MeSH
- Mean Platelet Volume * MeSH
- Case-Control Studies MeSH
- Blood Platelets * metabolism pathology MeSH
- Thrombosis blood drug therapy etiology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- anagrelide MeSH Browser
- Fusion Proteins, bcr-abl MeSH
- Quinazolines MeSH
- Platelet Aggregation Inhibitors MeSH
- Janus Kinase 2 MeSH
BCR/ABL-negative myeloproliferative neoplasms (MPNs) are considered to be acquired thrombophilic conditions. Persistently enhanced platelet activation has been described in polycythaemia vera and essential thrombocythaemia (ET), and shown to contribute to a higher risk of arterial and venous thrombotic complications. Recent studies have shown that mean platelet volume (MPV) and immature platelet fraction (IPF) can serve as useful markers of platelet activation and increased risk of thrombosis. The aim of the present study was to investigate the relationship between these parameters and thrombotic events in BCR/ABL-negative MPN. MPV values in patients with BCR/ABL-negative MPN were significantly higher than MPV values of healthy individuals (P < 0.001). No significant difference in MPV or IPF was observed between groups of patients with and without thrombotic complications (P = 0.441; P = 0.110); the difference in IPF values was close to the significance level for patients with ET (P = 0.073). Higher values of IPF were more frequently detected in patients with JAK2 V617F positivity (P = 0.030). These patients had higher MPV more frequently than others, and this difference was close to the significance level (P = 0.056). Further studies should validate the use of platelet parameters to identify patients at high risk.
See more in PubMed
Hematology Am Soc Hematol Educ Program. 2005;:409-15 PubMed
Thromb Res. 2002 May 15;106(4-5):171-7 PubMed
Br J Haematol. 2005 Feb;128(3):275-90 PubMed
Blood. 2013 Nov 28;122(23):3787-97 PubMed
Blood. 1992 Oct 15;80(8):1965-71 PubMed
Br J Haematol. 2000 Jul;110(1):116-24 PubMed
Br J Haematol. 2004 Jul;126(1):93-9 PubMed
Eur Heart J. 2001 Sep;22(17):1561-71 PubMed
J Clin Oncol. 2005 Apr 1;23(10):2224-32 PubMed
Platelets. 2012;23(5):336-43 PubMed
Br J Haematol. 2002 May;117(2):399-404 PubMed
Stroke. 2004 Mar;35(3):622-6 PubMed
Br J Haematol. 1969 Sep;17(3):225-9 PubMed
Blood. 2000 Dec 15;96(13):4261-6 PubMed
Arterioscler Thromb Vasc Biol. 2011 May;31(5):1215-8 PubMed
Semin Thromb Hemost. 2006 Apr;32(3):174-207 PubMed
Blood. 1984 Jun;63(6):1372-5 PubMed
Leuk Res. 2009 Jan;33(1):67-73 PubMed
JACC Cardiovasc Interv. 2010 Aug;3(8):828-35 PubMed
Am J Clin Pathol. 1981 Sep;76(3):289-93 PubMed
Int J Lab Hematol. 2009 Apr;31(2):199-206 PubMed
Haematologica. 2004 Feb;89(2):215-32 PubMed
Atherosclerosis. 2010 Dec;213(2):586-91 PubMed
Blood Rev. 2001 Sep;15(3):121-31 PubMed
N Engl J Med. 2005 Jul 7;353(1):33-45 PubMed
Thromb Haemost. 2013 May;109(5):846-53 PubMed
Thromb Haemost. 2008 May;99(5):930-5 PubMed
Thromb Haemost. 2009 Jan;101(1):151-6 PubMed
Am J Med. 2004 Nov 15;117(10):755-61 PubMed
J Thromb Haemost. 2010 Jan;8(1):157-62 PubMed
Blood Cells. 1989;15(1):108-21 PubMed
Am J Hematol. 2009 Feb;84(2):102-8 PubMed
Haematologica. 2006 Feb;91(2):169-75 PubMed
Blood Coagul Fibrinolysis. 1996 Mar;7(2):157-61 PubMed
J Thromb Haemost. 2010 Jan;8(1):148-56 PubMed
Exp Hematol. 2005 May;33(5):523-30 PubMed
Blood. 2011 Sep 1;118(9):2599-601 PubMed
Hematology Am Soc Hematol Educ Program. 2012;2012:571-81 PubMed
